Last reviewed · How we verify
NBP608 (Low Potency) — Competitive Intelligence Brief
phase 3
Biologic
Live · refreshed every 30 min
Target snapshot
NBP608 (Low Potency) (NBP608 (Low Potency)) — SK Bioscience Co., Ltd.. NBP608 is a low-potency compound developed by SK Bioscience with an undisclosed mechanism of action currently in phase 3 clinical development.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| NBP608 (Low Potency) TARGET | NBP608 (Low Potency) | SK Bioscience Co., Ltd. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- NBP608 (Low Potency) CI watch — RSS
- NBP608 (Low Potency) CI watch — Atom
- NBP608 (Low Potency) CI watch — JSON
- NBP608 (Low Potency) alone — RSS
Cite this brief
Drug Landscape (2026). NBP608 (Low Potency) — Competitive Intelligence Brief. https://druglandscape.com/ci/nbp608-low-potency. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab